Gene-sequencing group Illumina sees $1.47 bn Q2 impairment charge linked to Grail
Go back to Gene-sequencing group Illumina sees $1.47 bn Q2 impairment charge linked to Grail| (NASDAQ: GRAL) | Delayed: 60.16 +1.57 (2.68%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $58.59 | 52 Week High | $ | |||
| Open | $59.35 | 52 Week Low | $ | |||
| Day High | $61.37 | P/E | N/A | |||
| Day Low | $58.08 | EPS | $ | |||
| Volume | 596,715 | |||||
| Illumina, Inc. (NASDAQ: ILMN) | Delayed: 166.21 +3.74 (2.30%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $162.47 | 52 Week High | $196.47 | |||
| Open | $162.47 | 52 Week Low | $127.10 | |||
| Day High | $166.21 | P/E | 184.68 | |||
| Day Low | $160.65 | EPS | $0.90 | |||
| Volume | 1,486,923 | |||||
